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During a disease outbreak/pandemic situation such as COVID-19, researchers are in a prime position to
identify and develop peptide-based therapies, which could be more rapidly and cost-effectively advanced
into a clinical setting. One drawback of natural peptide drugs, however, is their proteolytic instability;
peptidomimetics can help to overcome this caveat. In this review, we summarize peptide and peptidebased therapeutics that target one main entry pathway of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which involves the host angiotensin-converting enzyme-2 (ACE2) receptor and viral
spike (S) protein interaction. Furthermore, we discuss the advantages of peptidomimetics and other potential targets that have been studied using peptide-based therapeutics for COVID-19.
First draft submitted: 29 May 2020; Accepted for publication: 30 June 2020; Published online:
16 July 2020
Keywords: ACE2 • angiotensin-converting enzyme-2 • antagonists • COVID-19 • peptide • peptidomimetics •
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Multiple zoonotic events since the turn of the millennium have resulted in disease outbreaks in the human
population, including influenza A, H1N1, H5N1, H7N9, Zika virus and Ebola virus. Outbreaks due to members
of the coronavirus family have been especially prominent in terms of transmission and mortality, beginning with the
emergence of SARS-CoV in 2002–2003 [1,2], followed by middle east respiratory syndrome coronavirus (MERSCoV) in 2012 [3] and SARS-CoV-2 (COVID-19) in late 2019 [4]. Key to the pathogenicity and infectivity of the
coronavirus family in humans is the spike (S) protein, a large trimeric crown-like complex forming the namesake
‘corona’ as observed on electron microscopy (Figure 1). Gain of function studies on circulating strains of coronavirus
in bats have evidenced the deterministic role of the S protein in selecting host species and tissue tropism [5].
The outbreak-associated coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2 share the commonality of
binding host peptidases as their entry receptors; alternatively, other coronaviruses can recognize post-translational
modifications such as glycans or adhesion molecules. Whereas MERS-CoV utilizes mainly dipeptidyl peptidase-4
(DPP4) [6], SARS-CoV and SARS-CoV-2 can enter human cells using angiotensin-converting enzyme-2 (ACE2)
(Figures 2 & 3) [7,8] as the primary receptor [9,10]. Aside from recognition and entry through the primary receptor,
secondary mechanisms exist for S protein mediated internalization, including through C-type lectins recognizing
high-mannose glycans on the S protein [11]. Viral entry is also proposed to be possible through an endocytosis
mechanism, with viral membrane fusion occurring in endosomes (reviewed in [9]).
The S protein of the SARS-CoV and SARS-CoV-2 is a heavily glycosylated [12] ∼180–200 kDa Type I transmembrane protein with its N-terminus residing on the outside surface of the virus, and a short C-terminal region
in the intramembrane viral space. The S protein comprises S1 and S2 subunits, which have a protease cleavage
site between them (S1/S2), while another protease cleavage site exists in the S2 region (S2 ). The S1 subunit
mediates initial host receptor binding to ACE2, while the S2 region contains the membrane fusion machinery
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Figure 1. Transmission electron micrograph of
SARS-CoV-2 virus particles, isolated from a patient.
Image captured and color-enhanced at the NIAID IRF in
Fort Detrick, Maryland. The spike protein (red) protrudes
from the virions resulting in the namesake ‘corona’.
Credit: NIAID-RML.
IRF: Integrated research facility.
Image used under creative commons license
(https://www.flickr.com/photos/niaid/49645402917/in/album-721577129
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Figure 2. Representation of
general structure of SARS-CoV’s and
host cell entry receptor ACE2. The
major viral proteins and RNA strand
are illustrated, these include the
envelope (E) protein, nucleocapsid
(N) protein, membrane (M) protein
and spike (S) protein, along with the
host entry receptor ACE2. The S
protein-ACE2 interaction is a crucial
mechanism of SARS-CoV entry into
host cells.
Figure 3. A close-up depiction of
the S protein and host ACE2
receptor. The viral S protein
(composed of S1 and S2 subunits) is
a trimeric membrane-embedded
glycoprotein. The RBD of the S1
region mediates initial binding with
the host entry receptor ACE2, a
transmembrane protein is
represented in light green. The
phospholipid bilayer of the viral
particle is represented in yellow
while host membrane phospholipid
bilayer is represented in orange.
RBD: Receptor-binding domain.

consisting of fusion peptide domains, and heptad-1 (HR1) and heptad-2 (HR2) domains that come together
during host receptor binding to mediate the bridging of viral and host cell membranes (Figure 4) [13,14]. Amino
acid (aa) residues within the C-terminal domain of the S1 subunit form the receptor-binding domain (RBD)
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Figure 4. A 2D-representation of the major domains of the SARS-CoV S protein. The S protein is composed of the
two subunits: S1 and S2. The S1 domain contains the NTD, the CTD, and is responsible for recognition and binding to
the host cell receptor. The S2 domain, responsible for membrane fusion, contains the FP, the heptad repeat regions
HR1 and HR2, the TM and CP tail. Two cleavage sites are indicated with arrows. The major peptide-based
therapeutics, indicated below, are associated S protein regions.
CP: Cytoplasmic; CTD: C-terminal domain; FP: Fusion peptide; NTD: N-terminal domain; TM: Transmembrane domain.

responsible for receptor specificity (Figure 3) [15,16]. The RBD of the virus has been characterized in the sequence
from the 2002–2003 outbreak of SARS-CoV and it resided in amino acids 318–510 of the S protein [17]. The
minimal-binding domain was determined to be on a short loop on the receptor-binding domain consisting of 14
amino acid residues (424–494) of the S protein in these previous studies. The RBD sequence has been compared
by the same group in SARS-CoV-2 and it resides in aa residues 331–524, furthermore, this report details sequence
variation and conserved residues between SARS-CoV, MERS and SARS-CoV-2. The sequence similarity in the S2
domain is more conserved between SARS-CoV and SARS-CoV-2, making this region a better potential drug target
for pan-SARS-CoV therapeutics [14,18].
Studies have determined that after host receptor binding (ACE2), the viral S protein is processed by host cell
proteases, including TMPRSS2 or likely other proteases [9,19]. Cleavage at the S1/S2 boundary releases the strain
exerted on the S2 subunit by the S1 subunit, leading to a dramatic conformational change. The S2 subunit
possesses fusion peptide (FP) domains, which help to mediate membrane binding between host and virus. The
second protease cleavage site S2 (Figure 3) exposes the FP permitting the formation of a six-helix bundle (composed
of three alpha helixes each from the heptad repeat 1 and 2 regions [HR1 and HR2]), which mediates host/virus
membrane fusion events, resulting in the delivery of the viral genetic material into the host cell. The tissue-specific
distribution of proteases capable of processing the S protein further narrows the tropism of particular coronaviruses
beyond the cell and organ-specific location of the primary receptor, ACE2 (reviewed in [19]).
The host receptor ACE2 is a type 1 transmembrane glycoprotein that functions enzymatically as a monocarboxypeptidase. Its main physiologic function is to convert the biologically active vasoconstrictive and inflammatory peptide angiotensin-2 (8 aa) to angiotensin (1–7) by cleavage of the C-terminal amino acid. It can also
act on angiotensin-1 (10 aa) (conversion to angiotensin (1–9), albeit with much less reported activity and affinity
for this peptide substrate (400-fold less) [20]. Tissue expression occurs in numerous organs and cell types, but high
expression was noted in lung alveolar epithelial cells and gut enterocytes [21], two important sites of SARS-CoV-2
exposure. The data on modulating endogenous ACE2 expression or its associated substrates are still in its infancy
and no firm conclusions can be drawn until further studies are designed and carried out. This area is well reviewed
by Perrotta et al. [22], and at present we feel the ACE2 substrates are less viable candidates for potential SARS
therapeutics due to the potential for side effects, and they will not be addressed herein.
As of present, there are a few published studies looking at therapeutics for directly targeting the ACE2–S protein
interaction that involve monoclonal antibodies, which have shown some promise in preclinical studies for SARSCoV-2 [23,24], many others are beginning to appear in preprint servers. These potential therapeutics combined with
the peptide and peptidomimetic candidates discussed herein, provide proof of concept for the potential value of
this target in combating SARS-CoV-2.
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Advantages & potential of peptides & peptidomimetics as therapeutics
During an outbreak situation, traditional drug discovery is not an efficient option as this process is inherently slow to
deal with the immense need for timely therapeutic solutions. There are several approaches that represent reasonable
alternatives such as drug repurposing, vaccination and immunotherapy. Both immunotherapy and vaccination
capitalize on peptide targets. Molecular details and the lessons learned from these strategies can be used to design
and develop potential peptide-based therapeutics.
Peptides are smaller fragments of proteins and are preferable for ease of synthesis in terms of time and cost. In
2010, over 100 peptide drug candidates were reported in clinical trials and in 2019, three new peptide drugs were
approved by the US FDA [25]. The advantages of peptides as drugs are rapid discovery, their specificity and affinity
to desired targets, and low toxicity due to the limited possibility for accumulation in the body. Early on, peptides
were considered poor drug candidates due to the inefficient and expensive synthesis processes, low bioavailability
and limited stability against proteolysis by peptidases in the gastrointestinal tract and serum (t1/2 of natural and
synthetic peptides are usually on the order of a few minutes). Thanks to technological advances, two chemical
methodologies: solution-phase synthesis in 1953 [26] and solid-phase peptide synthesis in 1963 [27] dramatically
dropped the cost of peptide manufacturing. The door of development for peptide-based therapeutics was widely
opened by introducing peptides with varying sequence length, side-chain reactivity and degree of modification and
incorporation of unnatural components.
To overcome the disadvantages of peptides as drug candidates, the field of peptidomimetics was introduced in early
1990s. A peptidomimetic candidate is usually based initially on a native peptide, which has been shown to inhibit
protein interaction or function and which is then modified artificially to enhance bioavailability, improve transport
through the blood–brain barrier (BBB), reduce the rate of clearance, and decrease degradation by peptidases [28,29].
There are numerous reported peptidomimetics [30], most of which were synthesized using altered solid-phase peptide
synthesis methods. Some examples of peptidomimetics include, D-amino acid substitutions, those with reduced
and functionalized amide bonds, peptoids, urea peptidomimetics, peptide sulfonamides, oligocarbamates, partial
or full retro-inverso peptides, azapeptides, β-peptides and N-modified peptides.
In this review, we summarize the main peptide-based therapeutics that have been described for SARS-CoV-2 and
SARS-CoV, which target the S protein–ACE2 interaction and entry process. Some of these are modified peptides
(lipidated) or some form of peptidomimetic. Our aim was to focus mainly on the S protein–ACE2-mediated entry
events (which includes subsequent membrane fusion steps), and we briefly highlight other potential targets for
peptide/peptidomimetic-based inhibition, such as viral proteases.
Investigations of peptide inhibitors targeting Spike–ACE2 interaction in COVID-19
Yan et al. [31] present cryo–electron microscopy structures of full-length human ACE2 with the RBD of the S
protein of SARS-CoV-2, the RBD is recognized by the extracellular peptidase domain of ACE2 mainly through
polar residues. These latest structural studies combined with previous research related to the RBD of SARS-CoV
(2003) provide a basis for the development of therapeutics targeting this crucial interaction.
Another area of therapeutic interest is the targeting of the membrane fusion events. The S2 domain of the
S protein, responsible triggering membrane fusion, includes the fusion peptide (FP), two heptad repeat regions
(HR1 and HR2), a transmembrane (TM) domain and a short cytoplasmic (CP) tail (Figure 4). Following receptor
binding, subsequent conformational changes in S2 creates a hydrophobic α-helical interface (six-helix bundle) as a
result of binding between HR1 and HR2 regions [32]. The membrane fusion event is initiated when hydrophobic
residues of the FP, insert in the host cell membrane. Due to the more conserved sequences between SARS-CoV and
SARS-CoV-2 in the S2 domains, targeting SARS-CoV-2 entry (membrane fusion) could potentially have greater
cross-functional success against coronavirus outbreaks.
Peptides derived from HR2 region were designed as SARS-CoV inhibitory peptides to disrupt fusion core
formation. In studies examining SARS-CoV (2003) membrane fusion, exogenously-administered HR2 peptides
blocked endogenous HR2 peptide binding with endogenous HR1 domains. The membrane fusion reaction was
therefore inhibited, and pore formation was prevented. HR2-based antagonist peptides were also speculated to
inhibit SARS-CoV-2, as suggested by the more highly conserved S2 subunits between SARS-CoV-2 and SARSCoV, with 92.6 and 100% overall identity in HR1 and HR2 domains, respectively. In early 2020, Xia et al. reported
their studies with the derivatives of SARS-CoV-2 HR2 peptides [33]. The group designed HR1- and HR2-derived
peptides, termed 2019-nCoV-HR1P (aa924–965) and 2019-nCoV-HR2P (aa1168–1203), respectively (Table 1),
and together with known pan-CoV fusion inhibitor (EK1 peptide) [34], explored their biological characteristics.
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Table 1. Major peptide therapeutic candidates in development for SARS-CoV and SARS-CoV-2.
Potential peptide
therapeutic

Target

Sequence/structure

Stage of development

Ref.

SARS-CoV-2 (COVID-19)
2019-nCoV-HR2P

HR1 domain of CoV S protein (MFM)

DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL

Preclinical in vitro models

[33]

EK1

HR1 domain of CoV S protein (MFM)

SLDQINVTFLDLEYEMKLEEAIKLEESYIDLKEL

Preclinical in vitro models

[33]

EK1C4 (lipopeptide)

HR1 domain of CoV S protein (MFM)

(N)EK1-GSGSG-PEG4-(Chol)

Preclinical in vitro and in vivo
models

[35]

IPB02

HR1 domain of CoV S protein (MFM)

ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELK(Chol)

Preclinical in vitro models

[36]

SBP1 (peptidase
domain of ACE2)

S protein-RBD

IEEQAKTFLDKFNHEAEDLFYQS

Preclinical in vitro models

[37]

Inhibitor 1–4

S protein-RBD

ACE2-based peptides

Proposed in theory

[38]

EK1

HR2 domain of CoV S protein (MFM)

SLDQINVTFLDLEYEMKLEEAIKLEESYIDLKEL

Preclinical in vitro and in vivo
models

[34]

HR1 and HR18

HR2 domain of S protein (MFM)

NGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTSTA

Preclinical in vitro models

[39,40]

P6

S protein-RBD

EEQAKTFLDKFNHEAEDLFYQSSGLGKGDFR

Preclinical in vitro models

[41]

SARS WW-III SARS
WW-IV
(derived from S2
subunit)

ACE2 receptor (MFM)

GYHLMSFPQAAP-HGVVFLHVTW

Preclinical in vitro models

[42]

[43]

SARS-CoV (COVID-2003)

IQKEIDRLNEVAKNLNESLIDLQELGK

GVFVFNGTSW-FITQRNFFS

RBD-11b

ACE2 receptor

YKYRYL

Preclinical in vitro models

S471–503

ACE2 receptor

ALNCYWPLNDYGFYTTTGIGYQPYRWVLSFEL

Preclinical in vitro models

[44]

SP10

ACE2 receptor

STSQKSIVAYTM

Preclinical in vitro models

[45]

MFM: Membrane fusion mechanism.

Using a SARS-CoV-2 S-mediated cell–cell fusion assay, the researchers demonstrated that 2019-nCoV-HR2P and
EK1 exhibited potent fusion-inhibitory activity with an IC50 of 0.18 and 0.19 μM, while 2019-nCoV-HR1P
showed no significant inhibitory activity at concentrations up to 40 μM. Furthermore, both 2019-nCoV-HR2P
and EK1 peptides showed significant inhibitory effect on SARS-CoV-2 pseudovirus infection in ACE2-expressing
293T cells, with IC50 values of 0.98 and 2.38 μM, respectively.
Peptide-based inhibitors usually have a short half-life in vivo, which can critically limit their therapeutic effects.
Emerging studies demonstrate that lipid-conjugated peptides exhibit dramatically increased antiviral potency and
improved pharmacokinetics. To improve the inhibitory activity, Xia et al. applied conjugation chemistry to EK1,
their work was published on 30th March in Cell Research [35]. Xia’s group generated a series of lipopeptides by
linking cholesterol (Chol) through an amino acid linker (GSG) and/or polyethylene glycol (PEG) spacer to the
C-terminus of EK1. Structure–activity relationship analysis suggested that ‘GSGSG-PEG4’ linker was optimal to
bridge both parts of the conjugates and identified that EK1C4 exhibited the most potent inhibitory activity against
SARS-CoV-2. EK1C4 was 241- and 149-fold more potent against SARS-CoV-2 S protein-mediated membrane
fusion and pseudovirus infection with IC50 ’s of 1.3 and 15.8 nM, respectively, as compared with EK1. EK1C4
has also been shown to be very effective against infection by SARS-CoV, MERS-CoV and other HCoVs. In
vivo, intranasally applied EK1C4 showed strong protection of mice against HCoV-OC43 infection. Results of
preinfection and postinfection treatment suggested that EK1C4 could be used to prevent and treat SARS-CoV-2
infection.
Recently, Zhu et al. [36] designed an HR2 sequence-based lipopeptide fusion inhibitor, named IPB02, which
showed high activities in inhibiting SARS-CoV-2. Inhibition by IPB02 on the SARS-CoV-2 S protein-mediated
cell–cell fusion was determined by a dual split protein-based cell fusion assay with an IC50 of 0.025 μM; inhibition on
SARS-CoV-2 pseudovirus infection was confirmed by a single-cycle infection assay with IC50 values of 0.08 μM. By
sequence truncation or extension, a group of lipopeptides around IPB02 was created. Structure activity relationship
studies of IPB02 revealed the important roles of the N- and C-terminal amino acid motifs for their bindings
and antiviral capacities. This group used circular dichroism spectroscopy to determine the structural properties
of their cholesterol conjugated peptides. Circular dichroism results showed that the cholesterylated peptides
exhibit significantly increased α-helical stability and target-binding affinity. This preprint report provides important
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information for understanding the entry pathway of SARS-CoV-2 and represents an ideal candidate for future
optimization.
SARS-CoV-2 initiates its entry into human cells by binding to ACE2 via the RBD of its S protein. Thus,
disrupting initial SARS-CoV-2 RBD binding to ACE2 is another strategy to inhibit the virus from entering human
cells. Peptide-based entry inhibitors are attractive candidates to inhibit the RBD–ACE2 interaction and may serve as
an effective antiviral drugs. Recently, Zhang et al. [37] demonstrated that the ACE2 peptidase domain (PD) α1 helix
is important for binding SARS-CoV-2-RBD by using molecular dynamics simulations on the cocrystal structure
of ACE2 and SARS-CoV-2-RBD [31]. The team chemically synthesized a natural 23-mer peptide (aa 21–43) from
the human ACE2 (hACE2) α1 helix, termed SBP1. Kinetic binding assays using bio-layer interferometry was
used to characterize the in vitro peptide–protein binding affinity. The results revealed that SBP1 strongly bound
to SARS-CoV-2 RBD with a disassociation constant (KD ) of 47 nM, which was comparable with that of the
full-length hACE2 [46]. SBP1 is a first-in-class peptide binder to SARS-CoV-2-RBD, which may effectively disrupt
the SARS-CoV-2–RBD/ACE2 interaction and block virus entry into human cells. However, the peptide needs to
be tested in human cells and in animal models of SARS-CoV-2 infection.
Some researchers are using computer simulations to identify promising small molecules or peptides before
conducting actual experiments in the lab. Applying computer-aided drug design techniques has emerged as an
efficient means to quickly search potential therapeutics against SARS-CoV-2.
Han et al. [38] recently published a study in the journal ACS Nano that described how to use computer modeling
to design compounds that mimic the spike protein’s natural target, ACE2. Using a recently solved X-ray crystal
structure of the RBD of SARS-CoV-2 when it is bound to ACE2, researchers identified 15 amino acids from
ACE2 that interact directly with the viral S protein. Then, four peptides (listed as inhibitors 1–4 in Table 1.)
containing this domain, or parts thereof, were designed and encompassed two sequential α-helices extracted from
the PD of ACE2. Molecular dynamic simulations revealed that the double α-helical peptides (such as inhibitors
2–4) were structurally stable and conformationally fitted to the RBD of SARS-CoV-2. Proposed in the report, at
least one peptide inhibitor was able to specifically bind to the spike protein and prevent SARS-CoV-2–RBD/ACE2
interactions. Barh et al. [47] and Huang et al. [48] also shared their initial computational findings in preprints posted
on preprints and BioRxiv, respectively. Using bioinformatics strategies, Barh et al. screened and designed several
potential anti-S protein peptides that may limit viral attachment and entry. Binding to SARS-CoV-2 S protein
RBD with the peptides was determined by the HPEPDOCK protein–peptide docking server. Ten peptides were
predicted as attractive therapeutics against SARS-CoV-2. Huang’s group designed thousands of peptide binders
that showed binding activity to SARS-CoV-2 in computational experiments. To enhance peptides’ binding affinity
to SARS-CoV-2 RBD, researchers redesigned the peptide sequence by applying structural bioinformatics and
sequence logo analyses. The top designed peptide binders were selected to run further experimental validations.
Thus, computational approaches may lead us to find potential inhibitory peptides against SARS-CoV-2, but in
vitro, and in vivo experiments are still required to evaluate and ensure their potential therapeutic efficacy.
Peptide-based antagonists from SARS-CoV (2003)
From research performed during the first coronavirus outbreak in 2003, several peptide-based antagonists were
also developed and tested and laid much of the groundwork for antagonists developed and studied during the
current 2019–2020 pandemic (i.e., EK1). It seems, however, that none have made it into clinical trials or have
been further advanced. Whether this occurred because of lack of funding, interest or unpublished negative results
in additional studies in unknown. Below we summarize the main peptide-based antagonists targeting the ACE2–S
protein interaction from the 2003 epidemic, which are listed in Table 1.
Heptad repeat regions (HR1 and HR2) of the S protein in SARS-CoV were identified as essential elements for
viral entry. They help the SARS-CoV virus attach to the ACE2 receptor; this process leads to membrane fusion
of the virus and the host cell. Xu et al. [39] studied the crystal structure of the SARS-CoV S protein fusion core
and identified HR2-18 peptide, which comprises residues 1161–1187, derived from the HR2 region and binds
to the relatively deep grooves on the surface of the central coiled coil. In another study, Yuan et al. [40] designed
and identified 25 synthetic peptides; two of these peptides corresponded to the HR regions, HR1-1 and HR2-18,
were identified as inhibitors, with EC50 values of 0.14 and 1.1 μM, respectively. The potency of these peptides was
studied by wild-type SARS-CoV assay, and only one peptide, HR2-18, was found to inhibit the entry of the SARSCoV with low activity. As expected, varying the amino acid sequences, addition or deletion of amino acid units
found to be detrimental for the inhibition activity. On the other side, Han et al. [41] performed alanine-scanning
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mutagenesis analysis to identify then design peptides that resembled residues critical for entry mediated by the
ACE2 receptor. They tested the activity of six synthetic peptides analogous to significant segments in ACE2. P6,
which is a peptide comprised two discontinuous fragments, aa 22–44 and 351–357 connected by glycine (Table 1).
This peptide potently inhibited SARS pseudovirus infection with an IC50 of approximately 0.1 μM. However, this
peptide has not been studied in an animal model yet. Sainz et al. [42] studied and identified novel peptides just
outside the HR sequences between the N- and the C-helical HR domains. Two peptides labeled SARSWW-III and
SARSWW-IV were recognized within the S2 subunit corresponding to the aa residues 1028–1049 and 1075–1093,
respectively. Based on the Wimley–White interfacial hydrophobicity scale (WWIHS), both peptides show potent
inhibition for the viral infectivity with 5.7 and 7.1 points, respectively. The authors reason the inhibition effect
to conformational changes required by the S2 protein during the fusion event. This group demonstrated that
SARSWW-III and SARSWW-IV inhibited viral plaque formation on Vero E6 cells by 90 and 83%, respectively, at
peptide concentrations of ∼30 μM. Such findings establish solid foundations for the development of new fusion
peptide inhibitors related to the HR-adjacent regions. These studies spotlight the HR region as a critical target for
the viral entry. These initial investigations have laid the groundwork for current research in targeting membrane
fusion related sequences in the S2 region that could be potent viral entry inhibitors or significant functional probes.
In a quest for potent small molecules that inhibit the SARS-CoV entry to the human cells, Struck et al. [43]
recognized the focal point of the viral protein that is necessary for the binding to the human cells. They identified
RDB-11b (Table 1), a hexapeptide (438YKYRYL443) in the RBD of the S protein of SARS-CoV that binds to the
human cell with recognizable affinity and specificity. RDB-11b found to reduce the viral infection of the epithelial
cells in the upper respiratory tract by a factor of 600. In a comprehensive screening for viral entry inhibitor peptides
of the SARS-CoV BJ01, Hu et al. [44] recognized S471–503 , a peptide that overlaps the RBD of SARS-CoV. This
peptide inhibits the viral entry by blocking the binding between the S protein RBD and the ACE2 receptor with
high specificity. S471–503 could inhibit the SARS-CoV infection of Vero cells in vitro with an IC50 of 4.0 μM (with
an EC50 value of 41.6 μM). After a few months, Ho et al. [45] reported another inhibitory peptide derived from S
protein, named SP-10 (aa residues 668–679). Using a biotinylated enzyme-linked immunosorbent assay, SP-10 was
found to significantly inhibit the binding of SARS-CoV S protein to ACE2, with an IC50 value of 1.88 ± 0.52 nM.
Further analysis by immunofluorescence assays and S protein-pseudotyped retrovirus infectivity indicated that
SP-10 can block both interactions of S protein and the infectivity of S protein-pseudotyped retrovirus with Vero
E6 cells. These peptide-based inhibitors provided the theoretical basis for the work done on SARS-CoV-2 and have
the potential to lead to potent cell fusion inhibitors against coronaviruses.
Other potential peptide therapeutics for SARS-CoV-2
As previously mentioned, endogenous ACE2 peptide substrates are also possible candidates for peptide-based
therapeutics, however, there has been some controversy with their potential use and side effects [49]. Recombinant
human ACE-2 (RhACE2) as a therapeutic for active disease was being tested in a small Phase II clinical trial to
evaluate its efficacy in SARS-Co-V-2 in China earlier this year, however the study was withdrawn for unspecified
reasons (NCT04287686). This protein (RhACE2-APN01) is now being tested in Phase II at multiple sites in three
countries (Germany, Denmark and Austria) with initial results expected by September 2020 (NCT04335136).
Proteases involved in both viral entry (host TMPRSS) and viral replication/transcription (3C-like protease M
or Mpro ) have also been studied as a potential target for SARS-CoV-2 therapeutics [9,50]. One group has also found
previously FDA-approved drugs that target viral Mpro inhibition that have shown some promise in preclinical and
clinical studies [51], while others have worked on peptidomimetic candidates that target Mpro with some success [52].
All of these targets and therapeutics require further investigation and optimization but seem to also have significant
potential in SARS-CoV-2.
Discussion & conclusion
In the immediate future, repurposed drugs and vaccines will be the first line of defense against COVID-19 [53], however drug resistance and other issues with vaccines (use in immunocompromised or immune deficient individuals)
should allow room for development of therapeutics targeting other pathways. Peptide-based therapeutics present
several advantages over traditional small-molecule drugs, including increased specificity and both cost and time
efficiency in synthesis. Although monoclonal antibodies also achieve this increased specificity, they require more
costly and labor-intensive synthesis methods. In addition, there has been some controversy over possible antibodymediated viral entry mechanisms, which could exacerbate disease [54]. The significance of the ACE2–S protein

future science group

10.4155/fmc-2020-0180

Review

VanPatten, He, Altiti, Cheng, Ghanem & Al-Abed

interaction in SARS-CoV-2 disease is currently under investigation using soluble RhACE2 (APN01) in Phase II
clinical studies overseas. Other preclinical studies with S protein-targeted neutralizing antibodies and peptide-based
inhibitors reviewed herein also provide strong evidence for the significance of this target in SARS-CoV-2. Going
forward, preclinical efforts for screening of peptide-based inhibitors should be performed in in vitro models [43],
before being tested in mice with humanized ACE2 [55], leading to further therapeutic development.
Future perspective
The field of peptidomimetics has opened a new door for the field of peptide-based therapeutics. The potential for
equivalent or even enhanced biological efficacy, extended bioavailability, and highly efficient synthesis and screening
mechanisms, positions these drug candidates as attractive options for development in disease outbreak situations.
The COVID-19 pandemic has benefitted from much of the research knowledge gained during the previous 2003
SARS-CoV outbreak. Similarities and differences among these two related viruses (SARS-CoV and SARS-CoV-2)
in specific biological interactions at the peptide level can be used to develop peptidomimetic-based drug candidates
to target the viral spike (S) protein-host receptor (ACE2) interaction.
Executive summary
Potential of peptide-based therapeutics in disease & pandemic situations
• Rapid, effective and cost efficient solutions are needed. Drug repurposing and immunotherapies (including
passive and active immunization) are the first line of defense and lessons learned from these strategies assist the
efficient design and development of peptide-based therapeutics.
COVID-19/SARS-CoV-2
• Lessons learned from related coronaviruses including SARS-CoV (2003) have been applied to the current
pandemic. Detailed structural analyses of the surface viral spike (S) protein and the main host entry receptor,
angiotensin-converting enzyme-2 (ACE2), have been used to develop potential peptide-based therapeutics.
Further studies in animal models and clinical settings are now underway.
Peptidomimetics
• These synthetically modified peptides have great potential for advancement due to their enhanced stability and
bioavailability. Several S protein- and ACE2-targeted peptidomimetics have been developed and are in various
stages of development and validation.
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